All In MedTech

Device Trial Radar · NCT06636175

64Cu-LLP2A for Imaging Hematologic Malignancies

Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

21

Actual

Start

Mar 20, 2025

Primary completion

Aug 28, 2026

Study completion Aug 28, 2026

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Oct 10, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.

Conditions

  • Multiple Myeloma
  • Low-Grade Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Small Lymphocytic Lymphoma
  • Chronic Lymphocytic Leukemia

Interventions

  • 64Cu-LLP2ADrug

    64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)

  • PET/CTDevice

    The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Organ dosimetry of participantsTime frame: Through completion of PET/CT scans (estimated to be up to 2 days)
  2. Safety and tolerability of new formulation of 64Cu-LLP2A as measured by number of participants with adverse eventsTime frame: From beginning of administration of 64Cu-LLPA2A through last phone call assessment (up to 7 days total)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.